Oragenics (NYSE:OGEN) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Down 4.5 %

Shares of Oragenics stock opened at $1.27 on Monday. The company has a market capitalization of $5.69 million, a PE ratio of -0.14 and a beta of 0.31. The stock’s 50 day moving average is $2.38. Oragenics has a 12-month low of $1.16 and a 12-month high of $7.74.

Oragenics (NYSE:OGEN) last announced its earnings results on Friday, March 29th. The company reported ($5.48) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Oragenics

Several hedge funds have recently modified their holdings of OGEN. Renaissance Technologies LLC boosted its position in shares of Oragenics by 388.9% in the first quarter. Renaissance Technologies LLC now owns 96,800 shares of the company’s stock valued at $33,000 after acquiring an additional 77,000 shares during the period. State Street Corp boosted its position in shares of Oragenics by 8.1% in the first quarter. State Street Corp now owns 495,563 shares of the company’s stock valued at $171,000 after acquiring an additional 37,338 shares during the period. Finally, Millennium Management LLC boosted its position in shares of Oragenics by 591.6% in the second quarter. Millennium Management LLC now owns 128,733 shares of the company’s stock valued at $45,000 after acquiring an additional 110,119 shares during the period. 18.71% of the stock is owned by institutional investors.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.